What is the true significance of donor-related cytomegalovirus transmission in the setting of facial composite tissue allotransplantation?

Transplantation Proceedings

Volumn 43, Issue 9, 2011, Pages 3516-3520

  Gordon, C R ^a,b   Abouhassan, W ^b   Avery, R K ^b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; AMOXICILLIN PLUS CLAVULANIC ACID; CEFTIZOXIME; CIDOFOVIR 3 HEXADECYLOXYPROPYL ESTER; COTRIMOXAZOLE; GANCICLOVIR; METRONIDAZOLE; PIPERACILLIN PLUS TAZOBACTAM; VALGANCICLOVIR; VANCOMYCIN; VORICONAZOLE;

AGE DISTRIBUTION; CANDIDA STOMATITIS; CONFERENCE PAPER; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; ENTEROBACTER; ENTEROCOCCUS; FACIAL COMPOSITE TISSUE ALLOTRANSPLANTATION; FACIAL TRANSPLANTATION; GEOGRAPHIC DISTRIBUTION; GRAFT RECIPIENT; GRAFT REJECTION; HUMAN; INFECTION RISK; MEDICAL LITERATURE; MOUTH INFECTION; PRIORITY JOURNAL; STAPHYLOCOCCUS EPIDERMIDIS; STOMATITIS; SYSTEMATIC REVIEW; VIRUS TRANSMISSION;

ANTIVIRAL AGENTS; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; FACIAL TRANSPLANTATION; HUMANS; OPPORTUNISTIC INFECTIONS; ORGAN TRANSPLANTATION; POSTOPERATIVE COMPLICATIONS; RISK; TISSUE DONORS; TRANSPLANTATION, HOMOLOGOUS;

EID: 81455139651     PISSN: 00411345     EISSN: 18732623     Source Type: Journal    
DOI: 10.1016/j.transproceed.2011.08.043     Document Type: Conference Paper

References (50)

1. M. Siemionow, and C.R. Gordon Overview of guidelines for establishing a face transplant program: a work in progress Am J Transplant 10 2010 1290
2. J.A. Fishman, and R.H. Rubin Infection in organ-transplant recipiens N Engl J Med 338 1998 1741
3. J.A. Fishman Infection in solid-organ transplant recipients N Engl J Med 357 2007 2601
4. J.-M. Dubernard, B. Lengele, and E. Morelon Outcomes 18 months after the first human partial face transplantation N Engl J Med 357 2007 2451
5. S. Guo, Y. Han, and X. Zhang Human facial allotransplantation: a 2-year follow-up study Lancet 372 2008 631
6. J.P. Meningaud, M.D. Benjoar, and M. Hivelin The procurement of total human face graft for allotransplantation: a preclinical study and the first clinical case Plast Reconstr Surg 2010 POST ACCEPTANCE June 15
7. L. Lantieri, J.-P. Meningaud, and P. Grimbert Repair of the lower and middle parts of the face by composite tissue allotransplantation in a patient with massive plexiform neurofibroma: a 1-year follow-up study Lancet 372 2008 639
8. C. Gordon, M. Siemionow, and F. Papay The world's experience with facial transplantation: what have we learned thus far? Ann Plast Surg 63 2009 572
9. M. Siemionow, F. Papay, and D. Alam First U.S. near-total human face transplantationa paradigm shift for massive facial injuries Lancet 374 2009 203
10. S. Schneeberger, S. Lucchina, and M. Lanzetta Cytomegalovirus-related complications in human hand transplantation Transplantation 80 2005 441
11. H. Bonnati, G. Brandacher, and R. Margreiter Infectious complications in three double hand recipients: experience fom a single center Transplant Proc 41 2009 517
12. American Society of Transplantation Infectious Disease Community of Practice Guidelines for the management and prevention of infectious complications after solid organ transplantation Am J Transplant 9 2009 S1
13. M. Siemionow, and C.R. Gordon IRB-based recommendations for medical institutions pursuing protocol Approval for face transplantation Plast Reconstr Surg 126 2010 1232
14. R.A. Fisher Cytomegalovirus infection and disease in the new era of immunosuppression following solid organ transplantation Transpl Infect Dis 11 2009 195
15. D.R. Snydman Counterpoint: prevention of cytomegalovirus (CMV) infection and CMV disease in recipients of solid organ transplants: the case for prophylaxis Clin Infect Dis 40 2005 709
16. C. Steininger Clinical relevance of cytomegalovirus infection in patients with disorders of the immune system Clin Microbiol Infect 13 2007 953
17. G. Opelz, B. Dohler, and A. Ruhenstroth Cytomegalovirus prophylaxis and graft outcome in solid organ transplantation: a collaborative transplant study report Am J Transplant 4 2004 928
18. J.A. Khoury, G.A. Storch, and D.L. Bohl Prophylactic versus preemptive oral valganciclovir for the management of.cytomegalovirus infection in adult renal transplant recipients Am J Transplant 6 2006 2134
19. Loewendorf A, Benedict CA: Modulation of host innate and adaptive immune defense by cytomegalovirus: timing is everything. J Intern Med 267:483
20. H. Einsele, M. Kapp, and G.U. Grigoleit CMV-specific T cell therapy Blood Cells Mol Dis 40 2008 71
21. A.J. Eid, R.A. Brown, and S.K. Arthurs A prospective longitudinal analysis of cytomegalovirus (CMV)-specific CD4(+) and CD8(+) T cells in kidney allograft recipients at risk of CMV infection Transpl Int 23 2010 506
22. I. Lautenschlager CMV infection, diagnosis and antiviral strategies after liver transplantation Transpl Int 22 2009 1031
23. N. Singh, C. Wannstedt, and L. Keyes Efficacy of valganciclovir administered as preemptive therapy for cytomegalovirus disease in liver transplant recipients: impact on viral load and late-onset cytomegalovirus disease Transplantation 79 2005 85
24. N. Singh Antiviral drugs for cytomegalovirus in transplant recipients: advantages of preemptive therapy Rev Med Virol 16 2006 281
25. P. Ljungman, P. Griffiths, and C. Paya Definitions cytomegalovirus infection and disease in transplant recipients Clin Infect Dis 34 2002 1094
26. R.H. Rubin The indirect effects of cytomegalovirus infection on the outcome of organ transplantation JAMA 261 1989 3607
27. C. Paya, A. Humar, and E. Dominguez Efficacy and safety of valganciclovir vs. oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients Am J Transplant 4 2004 611
28. A. Kalil, J. Levitsky, and E. Lyden Meta-analysis: the efficacy of strategies to prevent organ disease by cytomegalovirus in solid organ transplant recipients Ann Intern Med 143 2005 870
29. K. Coffman, C.R. Gordon, and M. SiemionoW Psychological outcomes with face transplantation: overview and case report Cuff Opin Organ Transplant 15 2010 236
30. C. Paradis, M. Siemionow, and F. Papay Ethical considerations in the first American face transplant Plast Reconstr Surg 126 2010 308
31. C. Paya, A. Humar, and E. Dominguez Efficacy and safety of valganciclovir vs. oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients Am J Transplant 4 2004 611
32. S.M. Palmer, A.P. Limaye, and M. Banks Extended valganciclovir prophylaxis to prevent cytomegalovirus after lung transplantation: a randomized, controlled trial Ann Intern Med 152 2010 761
33. F.L. Luan, L.J. Stackey, and J.M. Park Six month prophylaxis is cost-effective in transplant patients at high risk of cytomegalovirus infection J Am Soc Nephrol 20 2009 2449
34. E. Akalin, V. Sehgal, and S. Ames Cytomegalovirus disease in high-risk transplant recipients despite ganciclovir or valganciclovir prophylaxis Am J Transplant 3 2003 731
35. H. Kobayashi, M. Kobayashi, and R.L. McCauley Cadaveric skin allograft-associated cytomegalovirus transmission in a mouse model of thermal injury Clin Immunol 92 1999 181
36. C.R. Gordon, M. Siemionow, and B. Eghtesad A novel cadaver study quantifying the antigenic skin component accompanying comcomitant face and upper extremity transplantation Am J Transplant 10S 2010 57
37. C.R. Gordon, R.K. Avery, and W. Abouhassan CMV and other infectious issues related to face transplantation: specific considerations, lessons learned, and future recommendations Plast Reconstr Surg 2010 (In Press)
38. Painter W, Mossad S, Siemionow M, et al. First use of CMX001, a novel antiviral drug, for the suppression of cytomegalovirus infection in solid organ transplant patients: a case series. American Transplant Congress 2010, oral late-breaking abstract presentation, San Diego, Calif
39. C.E. Boeke, M.E. Pauly, and H. Hstch-Stock CMV antibody prevalence and seroincidence in plateletpheresis donors J Clin Apher 23 2008 63
40. B.N. Becker, Y.T. Becker, and G.E. Leverson Reassessing the impact of cytomegalovirus infection in kidney and kidney-pancreas transplantation Am J Kidney Dis 39 2002 1088
41. C.R. Gordon, M. Siemionow, and K. Coffman The Cleveland Clinic FACES score: a preliminary assessment tool for identifying the optimal face transplant candidate J Craniofac Surg 20 2009 1969
42. J.F. Delgado, N. Manito, and L. Almenar Risk factors associated with cytomegalovirus infection in heart transplant patients: a prospective, epidemiological study Transpl Infect Dis 2010, Oct 5
43. Sagadal, H. Rollag, and A. Hartmann Cytomegalovirus infection in renal transplant recipients is associated with impaired survival irrespective of expected mortality risk Clin Transplant 21 2007 309
44. R.K. Avery, and M.G. Michaels Strategies for safe living following solid organ transplantation Am J Transplant 9 2009 S252
45. Behring CSL: Biotherapies for Life. Clinical Communication: Prophylaxis vs. Preemptive Therapy for CMV in Solid Organ Transplantation
46. C.N. Kotton, and P.L. Hibberd Travel medicine and the solid organ transplant recipient Am J Transplant 9 suppl 4 2009 S273
47. L. Danzinger-Isakov, and D. Kumar Guidelines for vaccination of solid organ transplant candidates and recipients Am J Transplant 9 2009 S258
48. C.R. Gordon, and M. Siemionow Requirements for establishing a hand transplant program Ann Plast Surg 63 2009 262
49. C.R. Gordon, M. Siemionow, and J. Zins Composite tissue allotransplantation: a proposed classification system based on relative complexity Transplant Proc 41 2009 481
50. C. Strong An ongoing issue concerning facial transplantation Am J Transplant 10 2010 1115